medigraphic.com
ISSN 1561-3054 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cubana Med Trop 2022; 74 (2)

Characterization of Acinetobacter species, contributors to infections in Cuban hospitals

Pérez FYC, Quiñones PD, Carmona CY

Language: Spanish
References: 39
Page:
PDF size: 543.23 Kb.


ABSTRACT

Introduction: Acinetobacter spp. is a relevant pathogen in Cuba. The Acinetobacter baumannii-calcoaceticus complex is the main cause of severe infections. It is frequently isolated in intensive care units (ICU) and exhibits high resistance to most available antibiotics, including carbapenems.
Objective: To characterize the Acinetobacter isolates collected from patients admitted to Cuban hospitals.
Methods: A retrospective study was conducted at the Healthcare-Associated Infections Laboratory of “Pedro Kourí” Tropical Medicine Institute. The study included 278 isolates from 21 hospitals located in 9 provinces, stored from June 2011 to July 2012 in the culture collection of the laboratory. Species identification was based on biochemical tests and the susceptibility to 18 antibiotics was determined by the Bauer-Kirby method, except for colistin, for which the E-test (epsilometric method) was used. The variables under analysis were: Acinetobacter species, type of sample, type of healthcare service, antimicrobial susceptibility, and antimicrobial multi-resistance categorization.
Results: Acinetobacter baumannii-calcoaceticus complex prevailed, mainly in endotracheal fluid and blood samples. The ICU and the burn unit were the most affected healthcare services. High resistance percentages were observed to beta-lactams (76-94%), aminoglycosides (66-80%), and fluoroquinolones (60-89%). Tetracycline, doxycycline, and colistin were the most active antimicrobials. Multi-drug-resistance was observed in 73.5% of isolates, extensively-drug-resistance in 26.1%, and pan-drug-resistance in one isolate (0.4%).
Conclusions: Infections by Acinetobacter spp. constitute a serious health problem in the Cuban hospitals. High resistance to available antibiotics characterizes the isolates, which evidences the need to constantly monitor antimicrobial susceptibility and to reinforce the control measures, mainly in the ICUs.


REFERENCES

  1. Rodríguez Buenahora RD, Bustillo Zarate DE, Caicedo Sanchez DC, Cadena DC, Gómez C. Acinetobacter baumannii: patógeno multirresistente emergente. Med UIS. 2016 Aug [Acceso 24/10/2020];29(2):113-35. Disponible en: http://www.scielo.org.co/scielo.php?1.

  2. Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018 Aug [Acceso 22/09/2021];21(11):1249-60. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110297/2.

  3. Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics (Basel). 2020 Mar [Acceso 22/09/2021];9(3):[aprox. 29 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148516/3.

  4. Brisolla Tavares LC, de Vasconcellos FM, Vaz de Sousa W, Trevizani Rocchetti T, Mondelli AL, Martison Ferreira A, et al. Emergence and Persistence of High-Risk Clones among MDR and XDR A. baumannii at a Brazilian Teaching Hospital. Front Microbiol. 2019 [Acceso 13/10/2021];9(2898):[About. 8 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328482/pdf/fmicb-09-02898.pdf4.

  5. Vanegas Munera JM, Roncancio Villamil G, Jiménez Quiceno JN. Acinetobacter baumannii: importancia clínica, mecanismos de resistencia y diagnóstico. Rev CES Med. 2014 Jul [Acceso 12/11/2020];28(2):233-46. Disponible en: http://www.scielo.org.co/pdf/cesm/v28n2/v28n2a08.pdf5.

  6. paho.org [Internet]. Magnitud y tendencias de la resistencia a los antimicrobianos en Latinoamérica. RELAVRA 2014, 2015, 2016. Informe resumido; 16 Oct 2020 [Acceso 14/02/2022],[aprox. 1 pantalla]. Disponible en: https://www.paho.org/es/documentos/magnitud-tendencias-resistencia-antimicrobianos-latinoamerica-relavra-2014-2015-20166.

  7. Quiñones D. National Surveillance Program of Klebsiella spp., Acinetobacter and Enterococcus spp. in Cuba. The APUA Newsletter. 2012 [Acceso 20/05/2020];30(3):[about 3 p.]. Disponible en: https://apua.org/apua-newsletter7.

  8. Magiorakos A, Srinivasan R, Carey Y, Carmeli M, Falagas C, Giske S, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar [Acceso 13/10/2020];18(3):268-81. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21793988/8.

  9. Mac Faddin J. Pruebas bioquímicas para la identificación de bacterias de importancia clínica. 3.a ed. La Habana: Editorial Ciencias Médicas; 2006.

  10. CLSI. Performance and standards for antimicrobial susceptibility testing. Twenty-Nine Informational Supplement. CLSI document M100-S29. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

  11. Comité de l'Antibiogramme de la Société Française de Microbiologie. Recommandations 2010. Paris: Société Française de Microbiologie; 2010 [Acceso 03/03/2019]. Disponible en: Disponible en: http://www.sfm-microbiologie.org 11.

  12. Rada Cuentas J. Acinetobacter un patógeno actual. Rev Bol Ped. 2016 [Acceso 12/11/2021];55(1):29-48. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S102412.

  13. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin Microbiol Rev. 2016 Dec;30(1):409-47. DOI: https://doi.org/10.1128/CMR.00058-1613.

  14. Peleg AY, de Breij A, Adams MD, Cerqueira GM, Mocali S, Galardini M, et al. The Success of Acinetobacter Species; Genetic, Metabolic and Virulence Attributes. PLoS One. 2012 Oct;7(10):[about 11 p.]. DOI: https://doi.org/10.1371/journal.pone.004698414.

  15. Chan J, Halachev M, Loman N, Constantinidou C, Constantinidou C. Defining bacterial species in the genomic era: insights from the genus Acinetobacter. BMC Microbiology. 2012 Dec [Acceso 20/09/2020];12(302):[about 11 p.]. Disponible en: https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-12-30215.

  16. Lisboa Correa L, Batista Botelho LA, Carvalho Barbosa L, Simões Mattos C, Miron C, Teixeira de Castro CL, et al. Detection of blaOXA-23 in Acinetobacter spp. isolated from patients of a university hospital. Braz J Infect Dis. 2012 Nov [Acceso 12/11/2020];16(6):521-26. Disponible en: https://cyberleninka.org/article/n/360592/viewer16.

  17. Medell M, Hart M, Duquesne A, Espinosa F, Valdés R. Nosocomial Ventilator-Associated Pneumonia in Cuban Intensive Care Units: Bacterial Species and Antibiotic Resistance. MEDICC Review. 2013 Apr [Acceso 20/09/2020];15(2):26-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23686252/17.

  18. Barletta-Farías R, Pérez-Ponce L, Castro-Vega G, Pujol-Pérez M, Barletta-del-Castillo J, Dueñas-Pérez Y. Acinetobacter baumannii multirresistente: un reto para la terapéutica actual. Medisur. 2018 [Acceso 24/01/2022];16(2):[aprox. 12 p.]. Disponible en: http://medisur.sld.cu/index.php/medisur/article/view/378318.

  19. Gupta V, Garg R, Kaur M, Garg S, Attri AK, Chander J, et al. Prevalent resistance mechanisms in isolates from patients with burn wounds. Indian J Burns. 2015 Dec [Acceso 09/01/2021];23(1):[about 4 p.]. Disponible en: https://www.ijburns.com/article.asp?issn=0971-653X19.

  20. Rolain JM, Canton R, Cornaglia G. Emergence of antibiotic resistance: need for a new paradigm. Clin Microbiol Infect. 2012 Jul;18(7):[about 10 p.]. DOI: http://dx.doi.org/10.1111/j.1469-0691.2012.03902.x20.

  21. Kempf M, Rolain J-M, Diatta G, Said A, Bissoum S, Oleg M, et al. Carbapenem Resistance and Acinetobacter baumannii in Senegal: The Paradigm of a Common Phenomenon in Natural Reservoirs. PLoS ONE. 2012 Jun [Acceso 13/05/2020];7(6):[about 8 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380006/21.

  22. Casellas JM. Resistencia a los antibacterianos en América Latina: consecuencias para la infectología. Rev Panam Salud Publica. 2011 Dic [Acceso 14/02/2022];30(6):519-28. Disponible en: https://www.paho.org/journal/sites/default/files/06--Special--Casellas-519-528.pdf?ua=122.

  23. Aguilera Calzadilla Y, Díaz Morales Y, Guerra Martínez M, Sánchez Álvarez ML, Martínez Frometa M. Aislamientos de Acinetobacter spp. en infecciones asociadas a la asistencia sanitaria. Rev Cub Med Mil. 2019 Sep [Acceso 16/02/2022];48(3):e335. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572019000300002&lng=es23.

  24. Quiñones D, Carvajal I, Perez Y, Hart M, Perez J, Garcia S, et al. High prevalence of blaOXA-23 in Acinetobacter spp. and detection of blaNDM-1 in A. soli in Cuba: Report from national surveillance Program (2010-2012). New Microbes and New Infections. 2015 Jun;7:52-6. DOI: https://doi.org/10.1016/j.nmni.2015.06.00224.

  25. Sandor A. Cuadernillo de Uso Racional de Antimicrobianos y Otros Recursos (URAR). Comisión de uso adecuado de recursos. Sociedad Argentina de Infectología; 2019 [Acceso 24/10/2020]. Disponible en: http://www.afam.org.ar/textos/06_11_2019/aztreonam.pdf25.

  26. Principe L, Piazza A, Giani T, Bracco S, Caltagirone MS, Arena F, et al. Epidemic Diffusion of OXA-23-Producing Acinetobacter baumannii Isolates in Italy: Results of the First Cross-Sectional Countrywide Survey. J Clin Microbiol. 2014 Jul [Acceso 16/08/2021];52(8):[about 6 p.]. Disponible en: https://journals.asm.org/doi/full/10.1128/JCM.00291-1426.

  27. Novovic K, Mihajlovic S, Vasiljevic Z, Filipic B, Begovic J, Jovcic B, et al. Carbapemen-Resistant Acinetobacter baumannii from Serbia: Revision of Car O Classification. PLoS ONE. 2015 Mar [Acceso 16/08/2021];10(3):[about 16 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25822626/27.

  28. Ning B, Zhang C, Liu T, Ye S, Yang Z, Chen Z. Pathogenic analysis of sputum from ventilator-associated pneumonia in a pediatric intensive care unit. Exp Ther Med. 2013 [Acceso 25/05/2020];5(1):367-71. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524271/28.

  29. Moya A, Gómez R, Molina M, Mauri O, González José, Alfonso R. Emergencia de microorganismos multiresistentes en unidades de cuidados intensivos pediátricos y neonatales. La Habana; 2006 [Acceso 14/05/2020]. Disponible en: http://bvscuba.sld.cu/?read_result=cumed-31069&index_result=329.

  30. Pérez Morales L, Barletta Castillo JE, Quintana Hernández H, Reyes Rodríguez I, Otero Espino N. Estudio clínico, epidemiológico y microbiológico de pacientes con neumonía asociada a la ventilación mecánica ingresados en salas de cuidados intensivos. Medisur. 2012 [Acceso 13/08/2020];10(4):268-78. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X201200040000130.

  31. Espinosa F, Hart M, Halley M, Zamora R. Control multidisciplinario de la infección nosocomial en un hospital de nivel terciario. Rev Cubana Med. 2011 [Acceso 15/07/2020];50(1):40-8. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232011000100004&lng=es31.

  32. Hart M, Espinosa F, Halley M, Martínez M, Montes de Oca Z. Resistencia a antibióticos en cepas de Acinetobacter baumannii aisladas de enero a marzo del 2010 en el Hospital Clinico-quirúrgico Hermanos Ameijeiras. Rev Cubana Med. 2010 [Acceso 15/07/2020];49(3):218-27. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232010000300001&lng=es32.

  33. Tada T, Miyoshi-Akiyama T, Shimada K, Thanh TT, Anh LT, Truong N, et al. Dissemination of clonal complex 2 Acinetobacter baumannii strains co-producing carbapenemases and 16S rRNA methylase ArmA in Vietnam. BMC Infect Dis. 2015 Oct [Acceso 13/03/2021];15(433):[about 7 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26471294/33.

  34. CLSI. Performance and standards for antimicrobial susceptibility testing: Twenty-Third Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standars Institute; 2013.

  35. Durante Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013 Aug [Acceso 12/10/2021];57(3):349-58. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23616495/35.

  36. Taneja N, Kaur H. Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiol Insights. 2016 Mar [Acceso 20/11/2021];9(1):9-19. Available from: https://pubmed.ncbi.nlm.nih.gov/27013887/36.

  37. Azimi L, Talebi M, Pourshafie M-R, Owlia P, Rastegar Lari A. Characterization of Carbapenemases in Extensively Drug Resistance Acinetobacter baumannii in a Burn Care Center in Iran. Int J Mol Cell Med. 2015 Winter [Acceso 20/11/2021];4(1):46-53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359705/37.

  38. Servicio Antimicrobianos del INEI-ANLIS Dr. Carlos G. Malbrán. Desafíos en los métodos de evaluación de la sensilidad a polimixinas (colistina/polimixina b). Boletín informativo No. 30. 2017 septiembre [Acceso 16/02/2022];(30):1-15. Disponible en: http://antimicrobianos.com.ar/ATB/wp-content/uploads/2017/09/Boletin-PCC-NAC-Nro.30Metodos-de-Evaluacion-Sensibilidad-a-POLIMIXINAS-Sep-2017138.

  39. Servicio Antimicrobianos del INEI-ANLIS Dr. Carlos G. Malbrán. Protocolo Colistín DROP TEST. 2019 febrero [Acceso 16/02/2022]:1-3. Disponible en: http://antimicrobianos.com.ar/ATB/wp-content/uploads/2019/06/Protocolo-COLISTIN-DROP-TEST.pdf39.




2020     |     www.medigraphic.com